Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses a clinical trial for Setipiprant in the US, starting June 29th, with eligibility excluding recent users of minoxidil or finasteride. It encourages informed decision-making before signing up.

The conversation discusses the potential of Sanguisorba Officinalis Root Extract as a treatment for hair loss by inhibiting FGF-5. The user also mentions the product évolis, which is based on this extract but is only available in the US and Australia.

The user experiences an itchy scalp and finds relief using shampoo and Zyrtec, which helps with inflammation. They are unsure if the issue is related to histamines or seborrheic dermatitis.

The user has been using HIMS chewable for two months to address lifelong thin hair. They are considering a hair transplant as a potential solution.

The conversation humorously discusses the fictional "Post PP405 Syndrome" and the idea of starting a foundation or cult around it. It mentions skepticism about the effectiveness of PP405 and jokes about future therapies.

KX-826 failed Phase III trials due to high placebo effects, patient compliance issues, COVID-19 side effects, and detection method deviations. KX-826 is now marketed as a cosmetic and approved for combination with Minoxidil.

The conversation discusses the potential of topical rapamycin, metformin, and alpha-ketoglutarate (a-KG) for hair growth, with skepticism expressed about their effectiveness based on personal experience and existing use. It also mentions AICAR, known as cardarine or GW, which is not suitable for long-term use due to cancer risks in animal studies and its similarity to metformin.

A 26-year-old is experiencing unexpected hair shedding on the scalp, eyebrows, eyelashes, and body, along with greasy skin, and has decided to see a doctor. They are seeking advice and support.

Switching milk brands cleared scalp inflammation and other symptoms, but hair shedding continues. The user hopes shedding will stop as hair cycles progress.

The user experienced significant hair loss on the scalp, eyebrows, eyelashes, and pubic area, along with itchy, flaky skin and red patches. They have a history of eczema and dermatitis and suspect that stopping shampoo use and taking Ritalin may have contributed to the issue.

Oral minoxidil caused changes in hair texture, making it curly, dry, and lifeless, raising concerns about whether this is a temporary phase or permanent. Users discussed potential side effects of oral minoxidil, including heart issues, and suggested consulting a dermatologist and monitoring health markers.

A 19-year-old female is experiencing significant hair loss, with symptoms including alternating hair colors and thinning body hair. She seeks advice on coping and potential treatments, with suggestions to consult a dermatologist and check thyroid and hormone levels.

Kintor plans to release pyrilutamide foam and a plant-based Koshine by year-end, with GT20029 progressing in their pipeline. Users are pleased about the absence of propylene glycol (PG) in the new products.

RU58841 stopped scalp itching for the user, providing relief from persistent itchiness associated with hair loss. Some users reported side effects like chest pain, while others found relief with different treatments like mometasone.

Lichen Planopilaris (LPP) is an autoimmune condition causing permanent hair loss and fibrosis, often misdiagnosed. Treatments include pioglitazone, topical corticosteroids, anti-inflammatory medication, and Jak inhibitors.

A user found that scalp itch might be linked to inflammation rather than DHT alone and noticed hair improvement with certain cancer drugs. They also discovered that black seed oil relieved their scalp itch and are experimenting with a mix of essential oils for dry scalp, questioning if oils affect minoxidil absorption.

A user experienced heart palpitations and breathing issues while using oral finasteride and minoxidil for hair loss and plans to switch to generic finasteride and topical minoxidil. They also use Nizoral shampoo and are considering a moisturizing shampoo due to dryness and itchiness.

A user started using RU58841 for hair loss and experienced anxiety and physical discomfort. Other users suggested avoiding the treatment due to similar side effects and recommended alternative treatments like pyri.

Heavy nicotine use can lead to hair thinning and loss, but quitting can reverse these effects. The user noticed significant hair regrowth after quitting vaping.

The conversation discusses Melatonin's potential benefits for AGA and a product called "Asatex" by ASATONA AG. The company was uncooperative when contacted for purchase inquiries.

Hair loss treatment should target dermal white adipose tissue (DWAT) to restore hair follicles. Potential remedies include tocopherol (vitamin E), botox, rosiglitazone, niacin, kojyl cinnamate esters, and ADP355.

The user experienced a significant drop in libido and energy after taking saw palmetto, which they believe caused these changes. They are seeking advice and reassurance, with some users suggesting that the effects may not be permanent and could improve over time with a healthy lifestyle.

The conversation is about a user experiencing a tingling sensation and redness on their scalp, possibly related to hair loss treatments. Suggestions include using Nizoral shampoo and consulting a dermatologist, while the user mentions using oral finasteride.

MCT oil helps reduce dandruff, flaking, and itching, and may slow hair loss progression. Eliminating sugar and dairy also stabilizes hair loss, while zinc, sugar, and dairy can worsen scalp conditions.

A 20-year-old male has been experiencing hair loss for three years due to a vitamin D deficiency and has seen no improvement after 3.5 months of taking supplements. Another person suggested that if the hair loss follows a pattern, it might be regular baldness rather than due to the deficiency.

RU58841 in glycerin may cause less irritation than in PG form, but its effectiveness might be reduced. Users discuss the potential trade-off between irritation and efficacy.

The conversation discusses the safety study of PP405, emphasizing that early trials focus on safety rather than efficacy, and that any efficacy data from such a short study should be viewed skeptically. It also highlights that the information released is primarily for securing funding, and that meaningful efficacy results are expected in later phases.

A 12-year-old diagnosed with alopecia shares their experience and current treatments, including Dermovate, an unnamed cream, and liquid iron. The community offers support and encouragement.

David Barreto shared that a London-based research group is conducting a 12-month trial for a new nutraceutical treatment for pattern hair loss, designed with Dr. Carlos Puig. The trial aims to provide robust data, with results expected in 1-2 years, potentially representing a significant advancement since finasteride’s introduction in 1997.

Dr. Kang-Yell Choi's company, CK Regeon, is developing a drug called KY19382 for hair regeneration, which involves creating fine wounds to activate stem cells. The drug is in the formulation development stage, targeting markets like the US and Korea.